Drug Search Results
More Filters [+]

HQK-1004

Alternative Names: hqk-1004, hqk1004, hqk 1004
Latest Update: 2011-08-01
Latest Update Note: Clinical Trial Update

Product Description

HQK-1004 acts by inducing the expression of a gene for a viral protein that is the target of several common anti-viral drugs, including GCV, which eradicate virally infected cells. The gene that makes this target protein is present in EBV infected tumor cells, but it is not expressed, thus rendering these cells resistant to anti-viral therapeutics. (Sourced from: https://www.prnewswire.com/news-releases/hemaquest-pharmaceuticals-initiates-phase-2-clinical-trial-in-ebv-related-malignancies-100425419.html)

Mechanisms of Action: Fatty Acid

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: HemaQuest
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HQK-1004

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Lymphoproliferative Disorders|Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HQP-1004-EB-03

P2

Terminated

Lymphoproliferative Disorders

2010-11-01

P2 L-D AB

P2

Terminated

Lymphoproliferative Disorders|Lymphoma

2009-09-01

Recent News Events

Date

Type

Title